23 Jul 2008
Basingstoke, UK and Philadelphia, US – July 23, 2008
Shire Appoints Dr. Jeffrey Jonas Senior Vice President, R&D, Specialty Pharmaceuticals
– Shire Limited (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that Dr. Jeffrey Jonas has been appointed Senior Vice President of Research & Development for its Specialty Pharmaceuticals business. Dr. Jonas will be responsible for establishing the strategic direction of Shire Specialty Pharmaceuticals’ new product pipeline, including achievement of R&D milestones. Dr. Jonas has a broad range of experience in senior roles in research and development, and has been responsible for a number of successful INDs and NDAs for products spanning multiple therapeutic classes. Most recently, he served as Executive Vice President at Isis Pharmaceuticals in charge of clinical and pre-clinical development, regulatory affairs, quality assurance and compliance, and had broad responsibility for the product pipeline. Prior to joining Isis, Dr. Jonas was Chief Medial Officer and Executive Vice President at Forest Laboratories, Inc. He began his career at Upjohn Laboratories. Dr. Jonas has also been a successful entrepreneur. He founded and led AVAX Technologies, a leader in autologous cell therapy and individualized therapy. Dr. Jonas led AVAX through several successful financings, including an initial public offering in 1997. In 2001, he co-founded SCEPTOR Industries, a biotechnology company involved in biodefense surveillance. Dr. Jonas has published more than 70 scientific papers and chapters and has received a number of awards. Dr. Jonas received his M.D. from Harvard Medical School and completed a residency in psychiatry at Harvard. Shortly thereafter, he was appointed Chief Resident in psychopharmacology at McLean Hospital, Harvard Medical School. Michael Cola, President of Shire’s Specialty Pharmaceutical Business, commented: “We are fortunate to have someone with the breadth of experience of Dr. Jonas join our Specialty Pharmaceutical leadership team. He has a strong therapeutic background that complements our ADHD franchise, and also has scientific and commercial experience across a wide range of pharmaceutical and biologic areas, which will enable him to support Shire Specialty Pharmaceuticals current work in and expansion into other therapeutic areas. “ Dr. Jonas added: "Shire has a clear focus, where growth through product acquisition and product line enhancements in the company's key therapeutic areas continues to be a top priority. I'm excited to be joining Shire's experienced Specialty Pharma team and look forward to contributing to the advancement of its robust and promising pipeline." For further information, please contact:
Investor Relations Cléa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Media Jessica Mann (Rest of the World) +44 1256 894 280 Matthew Cabrey (North America) +1 484 595 8248 Jessica Cotrone (North America) +1 617 613 4640 Notes to editors SHIRE LIMITED
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website: www.shire.com "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
Statements included herein that are not historical facts are forward-looking statements. Such forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, Shire’s results could be materially affected. The risks and uncertainties include, but are not limited to, risks associated with: the inherent uncertainty of pharmaceutical research, product development including, but not limited to the successful development of JUVISTA® (Human TGFb3) and veleglucerase alfa (GA-GCB); manufacturing and commercialization including, but not limited to, the establishment in the market of VYVANSE™ (lisdexamfetamine dimesylate) (Attention Deficit and Hyperactivity Disorder (“ADHD”)); the impact of competitive products, including, but not limited to, the impact of those on Shire’s ADHD franchise; patents, including but not limited to, legal challenges relating to Shire’s ADHD franchise; government regulation and approval, including but not limited to the expected product approval date of INTUNIV™ (guanfacine extended release) (ADHD); Shire’s ability to secure new products for commercialization and/or development; and other risks and uncertainties detailed from time to time in Shire’s filings with the Securities and Exchange Commission, including Shire plc’s Annual Report on Form 10-K for the year ended December 31, 2007.
« Back to Shire news